Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

IMNN

Imunon Inc

Dec 13 • 04:00PM ET

0.8445

Dollar change -0.0052
Percentage change -0.61	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA BNTX NVAX DVAX INO VXRT PDSB AVIR ADMA CLOV

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.89	Insider Own	4.89%	Shs Outstand	14.50M	Perf Week	0.28%
Market Cap	12.18M	Forward P/E	-	EPS next Y	-1.13	Insider Trans	7.63%	Shs Float	13.79M	Perf Month	13.10%
Income	-19.45M	PEG	-	EPS next Q	-0.36	Inst Own	14.28%	Short Float	5.36%	Perf Quarter	-21.81%
Sales	0.00M	P/S	-	EPS this Y	22.22%	Inst Trans	-	Short Ratio	3.53	Perf Half Y	-24.60%
Book/sh	0.56	P/B	1.49	EPS next Y	32.86%	ROA	-99.63%	Short Interest	0.74M	Perf Year	-2.93%
Cash/sh	0.72	P/C	1.18	EPS next 5Y	-	ROE	-148.12%	52W Range	0.48 - 3.65	Perf YTD	24.19%
Dividend Est.	-	P/FCF	-	EPS past 5Y	26.62%	ROI	-217.34%	52W High	-76.86%	Beta	2.08
Dividend TTM	-	Quick Ratio	2.30	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	75.94%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	2.30	EPS Y/Y TTM	44.98%	Oper. Margin	-	RSI (14)	49.22	Volatility	6.20% 7.65%
Employees	33	Debt/Eq	0.16	Sales Y/Y TTM	-100.00%	Profit Margin	-	Recom	1.00	Target Price	13.20
Option/Short	No / Yes	LT Debt/Eq	0.09	EPS Q/Q	9.55%	Payout	-	Rel Volume	0.45	Prev Close	0.85
Sales Surprise	-	EPS Surprise	12.37%	Sales Q/Q	-	Earnings	Nov 07 BMO	Avg Volume	208.96K	Price	0.84
SMA20	4.28%	SMA50	-5.05%	SMA200	-26.47%	Trades		Volume	94,805	Change	-0.61%

Dec-10-24 08:05AM	IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001 (GlobeNewswire)
Nov-25-24 08:05AM	IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer (GlobeNewswire)
Nov-08-24 02:23AM	Imunon Inc (IMNN) Q3 2024 Earnings Call Highlights: Promising Clinical Advances Amid Financial ... (GuruFocus.com)
Nov-07-24 10:00AM	IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting (GlobeNewswire) -12.34%
08:05AM	IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
08:30AM	Loading…
Oct-31-24 08:30AM	IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024 (GlobeNewswire)
Oct-30-24 09:05AM	IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting (GlobeNewswire)
Oct-08-24 08:45AM	Imunon reports inducement grant under NASDAQ listing rule (TipRanks)
Oct-07-24 08:05AM	IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (GlobeNewswire) -5.56%
Sep-09-24 04:06PM	UPDATE - IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management (GlobeNewswire)
08:30AM	IMUNON's Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management (GlobeNewswire)
Aug-28-24 08:30AM	IMUNON to Host R&D Day on September 18th (GlobeNewswire)
Aug-14-24 08:00AM	IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire) -11.44%
Aug-07-24 05:04PM	IMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024 (GlobeNewswire) -7.76%
Jul-31-24 11:54AM	Imunons shares soar after IL-12 therapy success in Phase II trial (Pharmaceutical Technology) -59.34%
08:00AM	Loading…
08:00AM	IMUNON Announces $10 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules (GlobeNewswire)
Jul-30-24 08:00AM	IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001 (GlobeNewswire) +178.99%
Jul-29-24 04:05PM	IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow (GlobeNewswire)
Jun-24-24 08:30AM	IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer (GlobeNewswire)
Jun-05-24 08:30AM	First Participants Vaccinated in IMUNON's IMNN-101 Phase 1 Clinical Trial (GlobeNewswire)
May-15-24 08:30AM	Abstract on Phase 2 Study with IMUNON's IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
May-14-24 06:08AM	Q1 2024 Imunon Inc Earnings Call (Thomson Reuters StreetEvents) -9.12%
03:02AM	Imunon Inc (IMNN) Q1 2024 Earnings Call Transcript Highlights: Strategic Developments and ... (GuruFocus.com)
May-13-24 12:52PM	IMNN Stock Earnings: Imunon Beats EPS for Q1 2024 (InvestorPlace) +7.25%
09:00AM	IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study (GlobeNewswire)
08:00AM	IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-08-24 08:00AM	IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO (GlobeNewswire) +17.19%
May-06-24 11:00AM	IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024 (GlobeNewswire)
Apr-18-24 08:30AM	IMUNON's IND Application Cleared to Begin Human Testing of IMNN-101 (GlobeNewswire)
Apr-11-24 08:00AM	IMUNON Reports Compliance with Nasdaq Listing Requirements (GlobeNewswire) +6.21%
07:08PM	Loading…
Apr-01-24 07:08PM	Imunon, Inc. (NASDAQ:IMNN) Q4 2023 Earnings Call Transcript (Insider Monkey) +17.68% -9.33%
Mar-28-24 12:52PM	IMNN Stock Earnings: Imunon Beats EPS for Q4 2023 (InvestorPlace) +17.14%
08:00AM	IMUNON Reports 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-25-24 08:30AM	IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses (GlobeNewswire)
Mar-21-24 05:00PM	IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024 (GlobeNewswire) +6.42% +6.01%
Mar-13-24 08:00AM	IMUNON Files IND Application to Begin Human Testing of IMNN-101 (GlobeNewswire) -6.34%
Mar-12-24 05:00PM	IMUNON Announces Leadership Change (GlobeNewswire) -5.98%
Feb-29-24 08:30AM	Independent Lab Confirms Immunogenicity and Protection with IMUNON's IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5 (GlobeNewswire) +16.33%
Feb-27-24 08:30AM	Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON's IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer (GlobeNewswire) +16.37%
Feb-22-24 08:00AM	IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine (GlobeNewswire) +5.23%
Dec-11-23 08:30AM	IMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-20-23 06:45PM	Imunon, Inc. (NASDAQ:IMNN) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-14-23 09:00AM	IMUNON's VP of R&D to Present at the Vaccines Summit-2023 (GlobeNewswire)
08:00AM	IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Nov-07-23 08:30AM	IMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023 (GlobeNewswire)
Oct-23-23 08:30AM	IMUNON's Chief Science Officer to Present at the 3rd International Vaccines Congress (GlobeNewswire) +7.53%
Oct-19-23 08:30AM	IMUNON CEO Dr. Corinne Le Goff to Participate in a Panel Discussion on Pandemic Preparedness at the United Nations (GlobeNewswire)
Oct-18-23 08:30AM	IMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian Cancer (GlobeNewswire)
Oct-06-23 08:30AM	IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board (GlobeNewswire)
Sep-28-23 08:30AM	IMUNON Reports Interim Progression-Free Survival and Overall Survival Data in Phase 1/2 OVATION 2 Study in Advanced Ovarian Cancer (GlobeNewswire) -6.86%
Sep-26-23 08:30AM	IMUNON Releases Enterprise Video Highlighting the Companys Mission, Vision, Values, Breakthroughs and Technologies (GlobeNewswire)
Sep-18-23 07:08AM	IMNN: R&D Day Highlights Company Pipeline (Zacks)
Sep-13-23 08:30AM	IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4:00 p.m. ET (GlobeNewswire)
Sep-07-23 04:30PM	IMUNON to Host Virtual R&D Day on September 14th Beginning at 4:00 p.m. ET (GlobeNewswire) -5.74%
Sep-05-23 08:30AM	IMUNON to Participate in the H.C. Wainwright Global Investment Conference (GlobeNewswire)
Aug-25-23 12:09PM	Imunon Inc's Rocky Road Ahead: Unraveling the Factors Limiting Growth (GuruFocus.com) +9.01%
11:38AM	Is Imunon (IMNN) Modestly Overvalued? A Comprehensive Valuation Analysis (GuruFocus.com)
Aug-24-23 04:05PM	IMUNON Enters into CRADA for Preclinical Studies of PlaCCine Modality in Preventive Vaccines Against Lassa Virus (GlobeNewswire)
Aug-22-23 09:25AM	IMNN: Manuscript Preprint on COVID-19 DNA Vaccine Published (Zacks Small Cap Research)
Aug-15-23 06:11AM	Imunon, Inc. (NASDAQ:IMNN) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-14-23 08:30AM	IMUNON Expands Scientific Advisory Board with the Addition of Dr. Sachet Shukla (GlobeNewswire)
Aug-11-23 04:16AM	Q2 2023 Imunon Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-10-23 08:00AM	IMUNON Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Aug-07-23 08:30AM	Preclinical Data Showing Strong Immunogenicity and Protection with IMUNONs PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv (GlobeNewswire)
Aug-03-23 08:30AM	IMUNON to Hold Second Quarter 2023 Financial Results and Business Update Conference Call on Thursday, August 10, 2023 (GlobeNewswire)
Jul-12-23 05:00AM	KFC China Celebrates its 500th Store in Shanghai (PR Newswire)
Jun-27-23 12:00PM	IMUNON Unveils New Manufacturing Capabilities at Huntsvilles HudsonAlpha Biotech Campus (GlobeNewswire)
Jun-26-23 05:00PM	Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4) (GlobeNewswire)
Jun-12-23 08:30AM	IMUNON CEO to Discuss Companys Novel Non-viral DNA Therapy Option at the Mass General Brigham World Medical Innovation Forum 2023 (GlobeNewswire) +5.71%
Jun-08-23 08:30AM	IMUNONs CEO Presents Business Overview to Investors and Senior Biopharmaceutical Professionals at the BIO 2023 International Convention (GlobeNewswire)
May-30-23 08:00AM	IMUNON Presents PlaCCine Preclinical Data at the 2023 Viruses and Cells Gordon Research Conference (GlobeNewswire)
May-17-23 09:07AM	IMNN: Preclinical Data Suggests Testing BiWeekly Dosing of IMNN-001 (Zacks Small Cap Research)
May-12-23 02:03AM	Q1 2023 Imunon Inc Earnings Call (Thomson Reuters StreetEvents)
May-11-23 08:00AM	IMUNON Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -5.19%
May-04-23 08:30AM	IMUNON to Hold First Quarter 2023 Financial Results and Business Update Conference Call on Thursday, May 11, 2023 (GlobeNewswire)
Apr-19-23 08:30AM	IMUNON Presents Poster at the American Association for Cancer Research Annual Meeting Demonstrating Preclinical Immune Response of IMNN-001 (GlobeNewswire) +16.03%
Apr-13-23 08:13AM	IMNN: PLACCINE Technology Presented at Vaccine Technology Summit (Zacks Small Cap Research)
Apr-01-23 08:41AM	Imunon Full Year 2022 Earnings: EPS Misses Expectations (Simply Wall St.)
Mar-30-23 08:00AM	IMUNON Reports 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-23-23 08:30AM	IMUNON to Hold Fourth Quarter 2022 Financial Results and Business Update Conference Call on Thursday, March 30, 2023 (GlobeNewswire)
Mar-22-23 08:00AM	IMUNON Presents PLACCINE Data at Vaccine Technology Summit 2023 (GlobeNewswire)
Mar-21-23 04:30PM	Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4) (GlobeNewswire)
Mar-15-23 02:00PM	IMUNON Announces Abstract Accepted for Presentation at the American Association for Cancer Research Annual Meeting (GlobeNewswire)
Mar-01-23 08:45AM	IMUNON CEO Issues Letter to Shareholders (GlobeNewswire)
Feb-27-23 08:30AM	IMUNON and Break Through Cancer Commence Enrollment in a Phase 1/2 Clinical Study of IMNN-001 in Combination with Avastin in Advanced Ovarian Cancer (GlobeNewswire)
Jan-12-23 08:30AM	IMUNON Receives $1.6 Million from Sale of its New Jersey Net Operating Losses (GlobeNewswire)
Jan-05-23 08:30AM	IMUNON Enters into Collaborative Research Agreement with The Wistar Institutes Vaccine & Immunotherapy Center to Research IMUNONs PLACCINE Vaccine Platform (GlobeNewswire)
Dec-14-22 08:30AM	IMUNON Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4) (GlobeNewswire)
Dec-01-22 04:00PM	IMUNON Presentation at World Vaccine & Immunotherapy Congress Highlights PLACCINE Preclinical Proof of Concept and Key Competitive Advantages (GlobeNewswire) +5.00%
Nov-30-22 09:27AM	IMNN: Promising Preclinical Results for PLACCINE Platform (Zacks Small Cap Research)
Nov-22-22 08:30AM	IMUNON to Participate in the A.G.P./Alliance Global Partners Virtual Biotech Conference on November 30, 2022 December 1, 2022 (GlobeNewswire)
Nov-17-22 08:30AM	IMUNON Announces Strategic Investment in Transomic Technologies (GlobeNewswire)
Nov-14-22 08:00AM	IMUNON Reports Third Quarter 2022 Financial Results and Provides Business Update (GlobeNewswire)
Nov-10-22 08:30AM	IMUNON Enters into Technology Evaluation Agreement with Acuitas Therapeutics to Evaluate IMUNONs PLACCINE Plasmid DNA with Acuitas Lipid Nanoparticle Delivery System (GlobeNewswire)
Nov-07-22 08:30AM	Imunon to Hold Third Quarter 2022 Financial Results and Business Update Conference Call on Monday, November 14, 2022 (GlobeNewswire)
Oct-03-22 05:00PM	Imunon Appoints James E. Dentzer to its Board of Directors (GlobeNewswire)
08:00AM	Imunon Reports Partial Results from Ongoing Non-human Primate Study (GlobeNewswire)
Sep-29-22 05:00PM	Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4) (GlobeNewswire)
Sep-27-22 08:30AM	IMUNON to Present at Chardans 6th Annual Genetic Medicines Conference (GlobeNewswire)

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also engaged in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lindborg Stacy	President and CEO	Aug 15 '24	Buy	0.98	25,000	24,500	264,166	Aug 16 08:03 AM
Tardugno Michael H	Executive Chairman of Board	Aug 15 '24	Buy	1.03	25,000	25,750	353,346	Aug 16 08:01 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

IMNN

Imunon Inc

Upgrade your FINVIZ experience